Bristol-Myers Squibb and Adnexus in oncology collaboration

Oncology :: Bristol-Myers Squibb and Adnexus in oncology collaboration

Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus(TM) Therapeutics today announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for important oncology-related targets.

The goal of the collaboration is to discover and develop biologic compounds specifically tuned to modulate oncology targets of high clinical impact. Adnexus will deploy its PROfusion technology on up to six research programs to identify and deliver pre-clinical Adnectin candidates to Bristol-Myers Squibb. Bristol-Myers Squibb will be responsible for global development and commercialization activities, with Adnexus retaining a limited co-promotion right to the first product to achieve regulatory approval in the United States.

Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of approximately $30 million over the next three years to Adnexus, consisting of upfront and guaranteed research payments. Adnexus also is eligible to receive regulatory milestone payments of up to $210 million per product, as well as royalties on product sales and sales-based milestone payments.

"Bristol-Myers Squibb is focused on discovering and commercializing medicines to treat serious diseases with unmet medical need, including cancer, and we are committed to expanding our biologics portfolio because we believe these medicines have the potential to improve patient treatment options," said Francis Cuss, M.D., senior vice president of Discovery & Exploratory Clinical Research for Bristol-Myers Squibb. "The company continues to invest in new approaches to drug discovery, and this collaboration allows us to obtain key product rights to multi-functional Adnectins. We are excited about combining Bristol-Myers Squibb's broad experience in oncology research with Adnexus' new platform to explore novel biologic oncology treatments."

"Bristol-Myers Squibb has world class expertise in oncology, and we look forward to working together using our PROfusion and Adnectin combination to discover potential therapies for people with cancer," said John Mendlein, Ph.D., J.D., CEO of Adnexus. "Our recently published clinical data on Adnexus' selective VEGFR-2 blocker, Angiocept(TM), validates the broad utility of our proprietary Adnectin class, especially in cancer."




(Oncology :: Bristol-Myers Squibb and Adnexus in oncology collaboration published at SpiritIndia on Monday, February 26, 2007)

Oncology

Search more information on Oncology, Oncology books

Recently posted related articles on Oncology :

1. Cancer :: GSK & Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology
2. Cancer :: Elsevier launches Molecular Oncology
3. Oncology :: Bristol-Myers Squibb and Adnexus in oncology collaboration
4. Oncology :: Recruitment suspended into C.E.R.A. Phase II Oncology Trial
5. Lymphoma :: Berlex Oncology Evaluating Combination Therapy for Non-Hodgkin's Lymphoma

Most related articles:

- Oncology :: Bristol-Myers Squibb and Adnexus in oncology collaboration
- Colorectal Cancer :: ImClone & Bristol-Myers Squibb with Merck KGaA to develop Erbitux in Japan - 16.5
- Pharmaceutical :: Bristol-Myers Squibb Investment is the First to Span Discovery and Development in India - 15.3
- Head and Neck Cancer :: Study of Erbitux for Advanced Head and Neck Cancer - 13.9
- Diabetes :: Japan's Otsuka to develop saxagliptin for type 2 diabetes - 12.5
- Leukemia :: When Gleevec is not enough - 11.2
- HIV :: Bristol-Myers Squibb & National AIDS Fund announce World AIDS Day Campaign - 10.8
- Colorectal Cancer :: Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer - 10.1
- HIV :: REYATAZ, atazanavir sulfate for Adults With HIV-1 Infection - 9.6
- Hepatitis B :: Raising Awareness of Chronic Hepatitis B - 9.1

Oncology - recent related articles/news stories:

- New consensus on using APBI to treat breast cancer
- New test to predict chemotherapy response in breast cancer patients
- A man defeated HIV virus through bone marrow transplant
- Acupuncture reduces side effects of breast cancer treatment
- Short radiotherapy benefits breast cancer patients

»»   Salmonella :: Peter Pan & Great Value Peanut Butter Salmonella Outbreak
««   Anxiety :: FDA approves Lilly's Cymbalta for generalised anxiety disorder

Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT | Glossary | List

AYUSH = Ayurveda - Yoga - Unani - Siddha - Homeopathy -- Health articles

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com